Lexeo Therapeutics, Inc. (CIK: 0001907108) EDGAR, Information, Filings... CompaniesBIO.Com

Lexeo Therapeutics, Inc.

Mailing address
430 E. 29TH STREET, FLOOR 14, NEW YORK, Delaware, 10016
Phone
(212) 547-9879
State location
New York
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Filings
N/A

Lexeo Therapeutics, Inc. (CIK: 0001907108) is an American company incorporated in the state of New York. Head office is located at 430 E. 29TH STREET, FLOOR 14, NEW YORK, New York, 10016. Work in the industry 2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES). Lexeo Therapeutics, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
CHOLMONDELEY PAULA H	0001193675	Nov-02-2023	director
DIAZ REINALDO M	0001250086	Nov-02-2023	director
ENRIGHT PATRICK G	0001253886	Nov-02-2023	10 percent owner
Stampacchia Otello	0001361712	Nov-02-2023	10 percent owner
Tammenoms Bakker Juliet	0001431159	Nov-02-2023	10 percent owner
Altschuler Steven	0001458116	Nov-02-2023	director
Lundbeckfond Invest A/S	0001591046	Nov-02-2023	10 percent owner
Paster Anne-Mari	0001652863	Nov-02-2023	10 percent owner
Nessi Claudio	0001722050	Nov-02-2023	10 percent owner
Agger Mette Kirstine	0001722234	Nov-02-2023	director
Omega Fund VI, L.P.	0001757917	Nov-02-2023	10 percent owner
Longitude Venture Partners IV, L.P.	0001787456	Nov-02-2023	10 percent owner
Omega Fund VI GP Manager, Ltd.	0001826584	Nov-02-2023	10 percent owner
Omega Fund VI GP, L.P.	0001826592	Nov-02-2023	10 percent owner
Longitude Capital Partners IV, LLC	0001829169	Nov-02-2023	10 percent owner
COOPERSTONE BRENDA	0001931514	Nov-02-2023	director
Adler Eric	0001994972	Nov-02-2023	officer: Chief Scientific Officer
Davitian Bernard	0001994973	Nov-02-2023	director
McCormac Paul	0001994981	Nov-02-2023	officer: Chief Technical Officer
Robertson Jenny	0001995009	Nov-02-2023	officer: Chief Legal and Admin. Officer
Townsend Richard Nolan	0001995218	Nov-02-2023	director, officer: Chief Executive Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Lexeo Therapeutics, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0001415889-25-023188 ( Act) Size: 0 KB	Aug-27-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-25-022479 ( Act) Size: 0 KB	Aug-20-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-25-022477 ( Act) Size: 0 KB	Aug-20-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-25-022475 ( Act) Size: 0 KB	Aug-20-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-25-022473 ( Act) Size: 0 KB	Aug-20-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-25-022468 ( Act) Size: 0 KB	Aug-20-2025
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001959173-25-005296 (33 Act) Size: 0 KB	Aug-18-2025	001-41855 251227702
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001959173-25-005294 (33 Act) Size: 0 KB	Aug-18-2025	001-41855 251227682
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001959173-25-005292 (33 Act) Size: 0 KB	Aug-18-2025	001-41855 251227675
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001959173-25-005291 (33 Act) Size: 0 KB	Aug-18-2025	001-41855 251227660
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001959173-25-005289 (33 Act) Size: 0 KB	Aug-18-2025	001-41855 251227656
SCHEDULE 13G/A	Document	Acc-no: 0001104659-25-078747 (34 Act) Size: KB	Aug-14-2025	005-94231 251220609
SCHEDULE 13G	Document	Acc-no: 0000902664-25-003607 (34 Act) Size: KB	Aug-14-2025	005-94231 251218184
SCHEDULE 13G/A	Document	Acc-no: 0001415889-25-021791 (34 Act) Size: KB	Aug-14-2025	005-94231 251217123
SCHEDULE 13G/A	Document	Acc-no: 0001274173-25-000249 (34 Act) Size: KB	Aug-14-2025	005-94231 251216018
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000950170-25-108427 (34 Act) Size: KB	Aug-14-2025	001-41855 251214361
8-K	Document	Current report filing Acc-no: 0000950170-25-108426 (34 Act) Size: KB	Aug-14-2025	001-41855 251214359
SCHEDULE 13G	Document	Acc-no: 0001193125-25-180317 (34 Act) Size: KB	Aug-14-2025	005-94231 251214173
SCHEDULE 13G/A	Document	Acc-no: 0001104659-25-075208 (34 Act) Size: KB	Aug-07-2025	005-94231 251194354
424B3	Document	Prospectus filed pursuant to Rule 424(b)(3) Acc-no: 0001193125-25-153484 (33 Act) Size: KB	Jul-01-2025	333-288025 251094205

Recent 20 filings. View all Lexeo Therapeutics, Inc. filings

Overall rating 5.0

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Lexeo Therapeutics, Inc. overview
Lexeo Therapeutics, Inc. job
Lexeo Therapeutics, Inc. stock
Lexeo Therapeutics, Inc. ownership
Lexeo Therapeutics, Inc. CEO
Lexeo Therapeutics, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.